FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1296 October 29, 1998 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Figure 1A.

View larger version (310K): [in this window] [in a new window]   Figure 1. A 53-year-old man had human immunodeficiency virus (HIV)–related lymphoma, which had been in remission since 1987; a CD4+ lymphocyte count of 510 cells per cubic millimeter; and an HIV RNA load of 5000 copies per milliliter. The addition of the HIV-protease inhibitor indinavir (800 mg three times daily) to his antiretroviral regimen of zidovudine and lamivudine resulted in a decrease in the HIV RNA load to undetectable levels and an increase in the CD4+ count to 918 cells per cubic millimeter. Measurement of cholesterol (298 mg per deciliter [7.7 mmol per liter]; reference range, <193 mg per . . . [Full Text of this Article]

 

Related Letters:

Fat Distribution in AIDS
Teplitsky V., Halabe A., Aboulafia D. M., Bundow D.
Extract | Full Text  
N Engl J Med 1999; 340:969-970, Mar 25, 1999. Correspondence

This article has been cited by other articles:

• Gerschenson, M., Kim, C., Berzins, B., Taiwo, B., Libutti, D. E., Choi, J., Chen, D., Weinstein, J., Shore, J., da Silva, B., Belsey, E., McComsey, G. A., Murphy, R. L. (2009). Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 63: 1244-1250 [Abstract] [Full Text]  
• Phillips, A. N, Gazzard, B. G, Clumeck, N., Losso, M. H, Lundgren, J. D (2007). When should antiretroviral therapy for HIV be started?. BMJ 334: 76-78 [Full Text]  
• Grinspoon, S., Carr, A. (2005). Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. NEJM 352: 48-62 [Full Text]  
• Zhong, D.-s., Lu, X.-h., Conklin, B. S., Lin, P. H., Lumsden, A. B., Yao, Q., Chen, C. (2002). HIV Protease Inhibitor Ritonavir Induces Cytotoxicity of Human Endothelial Cells. Arterioscler. Thromb. Vasc. Bio. 22: 1560-1566 [Abstract] [Full Text]  
• Meininger, G., Hadigan, C., Rietschel, P., Grinspoon, S. (2002). Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am. J. Clin. Nutr. 76: 460-465 [Abstract] [Full Text]  
• McDermott, A. Y., Shevitz, A., Knox, T., Roubenoff, R., Kehayias, J., Gorbach, S. (2001). Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am. J. Clin. Nutr. 74: 679-686 [Abstract] [Full Text]  
• Rietschel, P., Hadigan, C., Corcoran, C., Stanley, T., Neubauer, G., Gertner, J., Grinspoon, S. (2001). Assessment of Growth Hormone Dynamics in Human Immunodeficiency Virus-Related Lipodystrophy. J. Clin. Endocrinol. Metab. 86: 504-510 [Abstract] [Full Text]  
• Khanlou, H., Adair, M., Farthing, C. (2000). Reduction of Buffalo Hump by Switching to Amprenavir in an HIV-Infected Patient. Arch Intern Med 160: 3499-3500 [Full Text]  
• Hadigan, C., Corcoran, C., Piecuch, S., Rodriguez, W., Grinspoon, S. (2000). Hyperandrogenemia in Human Immunodeficiency Virus-Infected Women with the Lipodystrophy Syndrome. J. Clin. Endocrinol. Metab. 85: 3544-3550 [Abstract] [Full Text]  
• Hadigan, C., Miller, K., Corcoran, C., Anderson, E., Basgoz, N., Grinspoon, S. (1999). Fasting Hyperinsulinemia and Changes in Regional Body Composition in Human Immunodeficiency Virus-Infected Women. J. Clin. Endocrinol. Metab. 84: 1932-1937 [Abstract] [Full Text]  
• Teplitsky, V., Halabe, A., Aboulafia, D. M., Bundow, D. (1999). Fat Distribution in AIDS. NEJM 340: 969-970 [Full Text]